#USA #Pittsburgh #MolecuLight #fluorescence imaging #Wound Management

MolecuLight to Exhibit at IPAWS Summit 2025

MolecuLight Corp., renowned worldwide for its innovative fluorescence imaging solutions, is excited to announce its participation in the upcoming 2025 International Post-Acute Wound Care Society (IPAWS) Summit. At this significant event, the company will unveil a groundbreaking consensus report crafted by top experts in wound care and surgery across the United States.

The report, entitled "Fluorescence Imaging in Surgical Wound Management: A Consensus-Based Approach," marks a critical advancement in surgical practices, advocating for the integration of fluorescence imaging as a core clinical tool. This technology is vital for effectively identifying and managing bacterial presence in surgical wounds, thereby enhancing patient outcomes and surgical efficacy.

During the IPAWS Summit, MolecuLight will showcase not only this pivotal document but also multiple scientific posters and live demonstrations of its advanced technology.

As Anil Amlani, CEO of MolecuLight, articulated, "This consensus signifies a monumental leap for our field, underscoring fluorescence imaging as an evidence-backed method for visualizing bacterial burden. It is essential for optimizing the management of surgical wounds." He further expressed enthusiasm about sharing their extensive portfolio of over 100 peer-reviewed publications, highlighting the clinical impact of MolecuLight's imaging technology on decision-making and workflow efficiencies.

Dr. Thomas E. Serena, a co-author of this consensus and a seasoned clinician experienced with MolecuLight technology, echoed these sentiments. He stated, "Having utilized fluorescence imaging extensively in wound care, I've observed firsthand its ability to transform our approach to managing bacterial loads." Dr. Serena emphasized that the insights provided in the new consensus are already revolutionizing practices in wound care, and he anticipates similar advancements in surgical contexts.

The consensus highlights how fluorescence imaging assists healthcare providers at every surgical stage:

1. Pre-Operative Stage: It identifies wounds with heightened bacterial levels, which is crucial for risk stratification, treatment planning, and patient education.
2. Intra-Operative Stage: The technology confirms clean surgical fields and directs accurate debridement, facilitating better integration of grafts and improved surgical outcomes.
3. Post-Operative Stage: It enables early detection of subclinical bacterial presence, tracks healing progression, and supports timely interventions, thereby mitigating risks associated with surgical site infections.

MolecuLight's commitment to enhancing wound care through fluorescence imaging is clearly supported by a robust foundation of over 100 peer-reviewed studies, reinforcing the transformative potential of this technology. This newly published consensus not only speaks to our dedication to improving wound healing outcomes but also aims to better patient quality of life while reducing healthcare expenses. With their advanced devices, such as the MolecuLight iX® and DX®, designed to deliver real-time detection of bacterial burden along with accurate digital wound measurement, MolecuLight stands at the forefront of medical imaging innovation. The MolecuLight DX® model, with its added thermal imaging capabilities, further exemplifies the company's commitment to comprehensive wound assessment.

The IPAWS Summit 2025 offers a platform for industry leaders and healthcare professionals to engage with innovative solutions like those presented by MolecuLight. As the landscape of wound care continues to evolve, the adoption of advanced imaging technologies will prove instrumental in shaping the future of surgical practices and patient care.

For further details, interested parties are encouraged to attend the MolecuLight exhibit at the IPAWS Summit 2025, where they can gain insights into how fluorescence imaging is setting new standards in surgical wound management.